Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
View/ Open
Date
2023-03-01ICR Author
Author
Ronchi, C
Brisken, C
Type
Journal Article
Metadata
Show full item recordAbstract
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866.
Collections
Research team
Endocrine control mechans
Language
eng
Date accepted
2022-12-22
License start date
2022-12-22
Citation
Clinical Cancer Research, 2022, pp. CCR-22-3374 -
Publisher
AMER ASSOC CANCER RESEARCH